Stoky
Back to explore
N
NoahListening
A
AshListening
0:00 / 0:00I. Strategic Overview and Business Segments
TECH logo

Bio-Techne Navigates 1% Sales Decline with 19% Operating Income Boost and Margin Gains

TECH10-QFiling Date: 11/6/2025
Bio-Techne Corporation
Description

What this story covers

Bio-Techne's Q1 FY2026 10-Q shows 1% net sales drop to $286.6M amid research funding pressures, offset by 3% Diagnostics growth. Gross margin rose to 65.6%, operating income up 19% to $47.7M via efficiency. Strong liquidity with $145M cash supports restructuring and innovation in spatial biology.

Story snapshot

CompanyBio-Techne Corporation
TickerTECH
VariantStandard detailed
Duration11:38
Filing type10-Q
PeriodQ1 2026
IndustryHealthcare & Pharmaceuticals
Accession0001104659-25-107053

Full Story Script

Content not available for this story.

Ask Noah

Question the story, source filings, and key financial signals.

Sign in to chat with Noah

Ask questions about revenue, margins, risk factors, filings and more. Noah uses retrieval-augmented analysis over raw financial disclosures.

Sign in